Key result
Among 53 Jordanian patients with congestive heart failure or atrial fibrillation, 49.05% had serum digoxin levels outside the therapeutic range, indicating a strong need for therapeutic drug monitoring.
Cross-Sectional (n=53)
No
Nearly half of Jordanian patients with CHF or AF on digoxin were outside the therapeutic range, highlighting the need for therapeutic drug monitoring and dose adjustment.
Answers are grounded in this paper and cite their sources.
May support TDM consideration in Jordanian CHF/AF patients; leaves open generalizability and outcome impact beyond this cross-sectional sample.
Therapeutic monitoring of digoxin and the population pharmacokinetic parameters in Jordanian patients were done. Fifty three patients visited cardiac department of Jordan University hospital participated in this study, thirty two patients had congestive heart failure (CHF), while twenty one patients had atrial fibrillation (AF). Ninety three blood samples were collected from those patients for the measurement of digoxin level using AxSYM digoxin II assay method. Serum creatinine and potassium levels were also measured, in addition to blood pressure and heart rate. Microsoft Excel and Statistica programs were used for kinetic and statistical analysis. NONMEM computer program ADVAN 4 and 2 compartment model was used for population analysis of digoxin parameters. The serum digoxin level ranged from 0.11-4 ng/ml. The percentage of all patients enrolled in this study that were out of therapeutic range was 49.05%. Serum digoxin levels were out of therapeutic range in 53.12% of patients with CHF and 42.85% in those with AF. The pharmacokinetic parameters for digoxin obtained in this study using traditional methods were: creatinine clearance CLcr (89.78 ± 45.61 ml/min), digoxin actual clearance CL (200.57 ± 154.52 L/day), volume of distribution V (541.57 ± 149.87L), t1/2(2.98 ± 2.05 day), elimination rate constant (0.41± 0.396 day-1). A strong correlation was also found between actual digoxin clearance with log dose normalized (R2=0.999), and t1/2 (R2= 0.875). No correlations were found between the log of the normalized dose and other pharmacokinetic parameters or potassium levels. The population pharmacokinetic parameter for digoxin obtained in this study were: CL (3.34L/h), Vc (3.27L), Vt (123L), inter-compartment clearance Q (72L/h), absorption rate constant KA (1.25h⁻¹). In Jordanian patients with either AF or CHF digoxin dose adjustment based on therapeutic drug monitoring principles is recommended. Digoxin pharmacokinetics were similar to those reported in non-Jordanian patients; estimated population pharmacokinetic parameters were in agreement with literature values.
No takes yet. Share an insight, caveat, or question.
Shaker et al. (2013) conducted a cross-sectional in Congestive heart failure (CHF) or atrial fibrillation (AF) (n=53). Digoxin therapy was evaluated on Percentage of patients with serum digoxin levels out of therapeutic range. Among 53 Jordanian patients with congestive heart failure or atrial fibrillation, 49.05% had serum digoxin levels outside the therapeutic range, indicating a strong need for therapeutic drug monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: